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Abstract
We report the case of a 59-year-old man who moved from Cape Verde to Massachusetts at the age of 29. He had
multiple sexual contacts with female partners in Cape Verde and with West African women in Massachusetts, as
well as multiple past indeterminate HIV-1 antibody tests. He presented to our facility with 2–3 months of
inappropriate behaviors, memory impairment, weight loss, and night sweats, at which time he was found to
have an abnormal enhancing lesion of the corpus collosum on brain magnetic resonance imaging (MRI). La-
boratory testing revealed a CD4 count of 63 cells/mm
3, positive HIV-2 Western blot, serum HIV-2 RNA poly-
merase chain reaction (PCR) of 1160 copies per milliliter and cerebrospinal ﬂuid (CSF) HIV-2 RNA PCR of 2730
copies per milliliter. Brain biopsy demonstrated syncytial giant cells centered around small blood vessels and
accompanied by microglia, which correlated with prior pathologic descriptions of HIV-2 encephalitis and with
well-described ﬁndings of HIV-1 encephalitis. Based on genotype resistance assay results, treatment guidelines,
and prior studies validating success with lopinavir-ritonavir, he was treated with tenofovir-emtricitabine and
lopinavir-ritonavir, which has led to virologic suppression along with steady neurologic and radiologic im-
provement, although he continues to have deﬁcits.
Introduction
O
fthe33millionpeoplecurrentlylivingwithHIV,only
1–2 million are infected with HIV type 2 (HIV-2), pre-
dominately in West Africa and countries with historical links
to West Africa, such as Portugal and former Portuguese col-
onies.
1 However, the infection is spreading with immigration
and increased globalization. The Center for Disease Control
and Prevention (CDC) reported 166 conﬁrmed cases in the
United States between 1987 and 2009, which is likely an un-
derestimateofthetrueprevalence.Thesecaseswereprimarily
reported in the northeastern part of the country, predomi-
nantly acquired by sexual contact, and 81% occurred in per-
sons born in West Africa.
2 Patients with HIV-2 tend to have a
more protracted course and less risk of symptomatic illness or
progressiontoAIDSthanpatientswithHIV-1.
3WhetherHIV-
2 is more or less neurotropic than HIV-1 is unclear; reports of
HIV-2 encephalitis are rare and primarily limited to autopsy
descriptions.
4 To our knowledge, this is the ﬁrst report of a
pathologic diagnosis of HIV-2 encephalitis via brain biopsy in
a living patient.
Case Report
A 59-year-old right-handed man presented with 2–3
months of inappropriate behaviors and progressive memory
impairment. Review of systems revealed unintentional
weight loss and night sweats without fever. He had a history
of indeterminate HIV antibody testing in the past, a prior
episode of proctitis, and a remote history of small bowel re-
section for obstruction. The patient moved to Massachusetts
from Cape Verde at age 29 and had not traveled back to Cape
Verde since that time. He reported sexual contact with female
partners while living in Cape Verde and with women from
Cape Verde after moving to Massachusetts. General physical
examination was notable for oral candidiasis. On neurologic
examination, the patient was distractable and disoriented
with markedly tangential speech. He demonstrated impair-
ment in attention, concentration, and motivation, as well as
registration and recall tasks; grasp and palmomental reﬂexes
were present on the right. Language was ﬂuent and visuos-
patial skills and praxis were intact. Cranial nerves, strength,
sensation, coordination, and gait testing were normal.
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383Laboratory studies revealed white blood cell count
3.81·10
3 cells/lL, hemoglobin 12.3g/dL, and albumin
3.4g/dL. T2-weighted magnetic resonance imaging (MRI)
demonstrated a conﬂuent area of signal abnormality within
the anterior corpus callosum extending into the right-greater-
than-left frontal subcortical white matter with no signiﬁcant
mass effect (Fig. 1A). T1-weighted images following intrave-
nous administration of gadolinium showed abnormal en-
hancement within the region of T2 signal abnormality (Fig.
1B–F). The callosal lesion showed no reduced or elevated
diffusivity. There was no meningeal enhancement.
Lumbar puncture yielded clear cerebrospinal ﬂuid (CSF)
with glucose 51mg/dL, protein 68.1mg/dL, red cell count 3
cells per microliter, and white cell count 1 cell per microliter.
Studies of the CSF that were negative included: gram stain
and culture, Venereal Disease Research Laboratory (VDRL),
and polymerase chain reaction (PCR) for herpes simplex vi-
rus, Epstein-Barr virus, John Cunningham (JC) virus, and
human herpesvirus 6. Cytology, gene-rearrangement studies,
and ﬂow cytometry of the CSF showed no evidence of ma-
lignancy. Blood tests for cryptococcal antigen and antinuclear
antibody were negative. Serum treponemal antibody and
Treponema pallidum particle agglutination assay were positive;
rapid plasma reagin was nonreactive. Nonspeciﬁc enzyme-
linked immunosorbent assay (ELISA) of the blood for anti-
body against HIV (types 1 and 2) was positive. Western blot
for antibody against HIV-1 was indeterminate, with strong
band at p31 and weak bands at p24 and p40. No HIV-1 RNA
wasdetectedbyplasmaPCR.HIV-2speciﬁcWesternblotwas
positive (Focus Diagnostics, Inc., Cypress, CA). CD4 cell
count was 63 cells/mm
3 (5% of the total lymphocyte count).
Plasma viral load was 1160 copies per milliliter and CSF viral
FIG. 1. Axial T2-weighted ﬂuid-attenuated inversion recovery (FLAIR) images reveal abnormal hyperintense signal within
the genu of the corpus callosum (A, arrow) and extending into the right (A, arrowhead) greater than left frontal subcortical
white matter. Axial T1-weighted images obtained after administration of gadolinium reveal patchy abnormal enhancement
extending throughout the genu of the corpus callosum (B, arrow) and into the right (B, arrowhead) greater than left
subcortical white matter. Coronal T1-weighted images obtained after administration of gadolinium show patchy abnormal
enhancement within the right subcortical white matter (C, arrow) and the genu (D, arrow) and body (E, F, arrows) of the
corpus callosum. Axial T2-FLAIR images after three months of ARV therapy show an interval increase in abnormal signal
throughout the right greater than left frontal subcortical white matter (G), evidence of prior biopsy (G, arrow) and resolution
of abnormal enhancement (H).
384 WOOD ET AL.load was 2730 copies per milliliter by previously described
quantitative HIV-2 PCR testing methods.
5
A stereotactic biopsy of the right frontal subcortical white
matter was performed due to suspicion of lymphoma or other
inﬁltrating neoplasm. Pathologic evaluation of the biopsy
specimen revealed syncytial giant cells primarily centered
around small blood vessels and focally accompanied by mi-
croglia, most consistent with HIV encephalitis (Fig. 2). Im-
munohistochemical stain for CD163 (activated macrophages)
revealed the lesion to be composed entirely of macrophages
and active microglia without evidence of other inﬂamma-
tory cells.
Immunohistochemical stain for HIV-1/2 p24 antigen was
performed and most intensely stained within macrophages
and syncytial cells. Immunohistochemistry for JC virus was
positive in rare scattered cells.
Antiretroviral therapy was initiated with tenofovir-em-
tricitabine and lopinavir-ritonavir. The patient also received
empiric intravenous penicillin for possible neurosyphilis.
Genotype assays of the serum and CSF isolates (done by
previously described HIV-2 genotype resistance assay meth-
ods) later demonstrated non-nucleoside reverse transcriptase
inhibitor resistance and reduced protease inhibitor suscepti-
bility.
6Repeatplasmatestingafteronemonthofantiretroviral
therapy demonstrated undetectable HIV-2 RNA (<100 copies
per milliliter).
5 Three months after beginning therapy, brain
MRI demonstrated an interval increase in abnormal T2 hy-
perintensity throughout the right greater than left frontal
subcortical white matter with resolution of the abnormal en-
hancement in this region (Fig. 1G and H). These changes were
felt to represent resolution of active inﬂammation and per-
sistence of encephalomalacia from prior inﬂammation. Four
months into treatment, his CD4 cell count had increased to
183 cells/mm
3 and cognition had modestly improved, but
deﬁcits in memory and executive function persisted. Neuro-
logic examination was notable for continued impaired atten-
tion, perseveration on clock drawing, and the presence of
utilization behavior and frontal release signs with intact lan-
guage, calculations, and visuospatial skills.
Discussion
Central nervous system (CNS) complications of HIV-1 in-
fection have been well described and neuropathologic ab-
normalities have been found at autopsy in as many as 80-90%
of HIV-1–infected patients.
7 Neurologic disease associated
with HIV-2 is less well understood; reports are uncommon
and often limited to opportunistic infections.
4,7 Descriptions
of HIV-2 encephalitis are especially unusual. Our patient was
evaluated for other CNS infections, autoimmune processes,
vasculitides, and malignancies but none were found. Imaging
characteristics, negative CSF VDRL, and pathology from
FIG. 2. Histologic images from the brain biopsy performed in this patient are shown. A hemotoxylin and eosin stained
section (400·magniﬁcation) demonstrates the presence of macrophages, giant cells, and a microglial nodule which were the
only abnormalities found in the tissue (A). Immunohistochemistry for CD163, a marker of activated macrophages, shows that
all cells in the microglial nodules including the giant cells were positive (200·magniﬁcation; B). Immunohistochemistry for
HIV-1/2 p24 antigen (400·magniﬁcation) demonstrates the activated macrophages to harbor p24 antigen including giant
cells, a feature shared between HIV-1 and HIV-2 encephalitis (C). Immunohistochemistry for JC virus shows scattered
positive cells (200·magniﬁcation; D).
HIV-2 ENCEPHALITIS 385brain biopsy made it unlikely that the cause of his symptoms
was neurosyphilis, despite positive serum treponemal anti-
bodies. Brain biopsy did reveal scattered glial nuclear posi-
tivity with antibody to polyoma virus (which recognizes JC,
BK, or SV40 virus proteins), but the paucity of positively
stainedcells,lackofdemyelination,andnegativeCSFJCvirus
PCR made progressive multifocal leukoencephalopathy
(PML) extremely unlikely. Antibody positivity may relate to
focal incidental activation or latency rather than active dis-
ease, as latent JC virus has been shown to exist in the brains of
individuals without PML.
8
To our knowledge, this is the ﬁrst reported case of HIV-2
encephalitis diagnosedbybrain biopsyinalivingpatient.The
histopathology of HIV-2 encephalitis was described in a 2003
case series in which brain specimens from eight patients were
reviewed at autopsy (six HIV-2 infected and two HIV-1/HIV-
2 dually infected).
9 HIV-2 p26 was detected in brain tissue in
four of the HIV-2 cases and one of the dually infected using
immunohistochemistry. The productively infected cells were
eithermicrogliaorinﬁltratingmacrophages. Thepathologyof
our patient was comparable to that described in this report
and was also similar to that of HIV-1 encephalitis, which
typically involves collections of multinucleated giant cells,
microglialnodules,andmacrophageaggregatesaroundsmall
blood vessels in the central white matter.
10
Two prior case reports describe patients with HIV-2 en-
cephalitis conﬁrmed by pathology at autopsy.
7,11 First, a 27-
year-old Senegalese woman was diagnosed with HIV-2 in the
setting of Pneumocystis jirovecii pneumonia and suppressed
CD4countandsubsequentlydevelopedCMVandToxoplasma
retinitis that resolved with treatment. She then developed
progressive cognitive decline, depression, and aggression
with cortical atrophy on computed tomography, and no other
CNS infection was identiﬁed. Histopathology on autopsy
demonstratedchangesconsistentwithHIV-2encephalitisand
HIV-2 was detected in brain tissue by immunohistology, PCR
and in situ hybridization. Second, a 31-year-old Portuguese
woman developed diplopia and photophobia followed by
fever, malaise, and gait instability then forgetfulness and
hallucinations. She was found to have an enhancing right
parietal mass and seropositivity for HIV-2 infection and later
died. Autopsy demonstrated multiple abscesses (including
the right parietal lobe) with Toxoplasma bradyzoites and ta-
chyzoites. Additionally, microglial nodules, multinucleated
giant cells, and perivascular mononuclear cell inﬁltration
were seen diffusely throughout the subcortical white matter,
basal ganglia, and brainstem.
Very few studies have compared rates of encephalitis
caused by HIV-2 infection to HIV-1. In one Cote D’Ivoire study
that included autopsies of HIV-1–positive, HIV-2–positive, and
HIV-negative patients, encephalitis secondary to HIV-2 ap-
peared to be more common: 7 of 40 patients with HIV-2 (18%)
had multinucleated giant cell encephalitis compared to 1 of 174
patients with HIV-1 (1%).
12 Other comparisons have found
equivalent rates of encephalitis between HIV-1 and HIV-2 but
didnot establishwhether HIV directly caused the encephalitis.
13
Based on these limited data and rare case reports, it is difﬁcult to
compare the relative neurotropism of HIV-1 and HIV-2.
Optimal treatment for HIV-2 infection is less clearly de-
ﬁned than for HIV-1 and is hindered by lack of randomized
clinical trial data and no commercially available viral load or
resistance assays (our viral load and resistance tests were
performed by a research laboratory). In terms of antiretroviral
therapy, most guidelines and experts recommend two NRTI’s
along with a ritonavir-boosted PI; HIV-2 is known to be in-
trinsically resistant to NNRTI’s.
1 Genotype resistance testing
for our patient demonstrated high-level resistance to nevir-
apine, efavirenz, fosamprenavir and nelﬁnavir. One study
demonstrated positive response at 2 years in 29 HIV-2–
infected patients taking regimens with lopinavir-ritonavir,
which led us to choose this agent.
14 Our patient responded
well to tenofovir-emtricitabine plus lopinavir-ritonavir, with
virologic suppression, immunologic recovery, radiologic im-
provement, and slow clinical improvement, although he re-
mains far from his baseline.
Another important aspect of the case is that the patient had
a history of prior indeterminate HIV-1 antibody tests but had
never been tested for HIV-2. It is important to remember that
routine ELISA tests at most institutions do not differentiate
between HIV-1 and HIV-2 and reﬂexive Western blots are
speciﬁc to HIV-1. The CDC recommends checking speciﬁc
HIV-2 tests for the following persons: sex partners of a person
from a country where HIV-2 is endemic, sex partners of a
person known to be infected with HIV-2, persons who re-
ceived a blood transfusion or nonsterile injection or shared
needles in an endemic country, children of women with risk
factors forHIV-2orknowntobeinfectedwithHIV-2,orwhen
there is suspicion for active HIV disease with an HIV-1
Western blot that is negative or results in an unusual pattern.
With HIV-2 infection, the HIV-1 Western blot often shows an
indeterminate pattern with GAG bands and POL bands but
noENVbands.
15StudieshaveshownthatAfricanimmigrants
in the United States are unlikely to seek routine HIV testing
(only 4% diagnosed by routine testing in one study), com-
monly present withlate-stage HIV disease, and are frequently
infected with non-subtype B strains.
16 This underscores the
need for careful consideration of infection in at-risk patients.
In conclusion, neurologic disease attributable to HIV-2 in-
fection is not well described in the literature and the limited
accessibility of diagnostics and treatment data makes it a
challenging clinical illness. It is essential to consider HIV-2 as
a possible cause of infection in patients from at-risk countries
or with indeterminate HIV antibody results. It is also impor-
tant to remember that while most often a protracted and mild
illness, HIV-2 can sometimes progress to severe disease and
signiﬁcant neurologic impairment as in the case presented.
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